Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma

References

• Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229–1253. doi:10.1182/blood.2022015851
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi:10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Yoon SE, Song Y, Kim SJ, et al. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in asian patients: a multinational, multicenter, prospective registry study in Asia. The Lancet Regional Health – Western Pacific. 2021;10:100126. doi:10.1016/j.lanwpc.2021.100126
   PubMedGoogle Scholar
• Vose J. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Helenowski IB, Bryan LJ, et al. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. Br J Haematol. 2015; 168(5):708–718. doi:10.1111/bjh.13202
   PubMed Web of Science ®Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; Oct15(10):1467–1475. doi:10.1093/annonc/mdh392
   PubMed Web of Science ®Google Scholar
• Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the swedish lymphoma registry. Blood. 2014; 124(10):1570–1577. doi:10.1182/blood-2014-04-573089
   PubMed Web of Science ®Google Scholar
• Ellin F, Jerkeman M, Törnqvist J, et al. Impact of comorbidity on survival in peripheral T-cell lymphomas: a Swedish lymphoma registry study. Hematol Oncol. 2018; 36(1):159–165. doi:10.1002/hon.2428
   PubMed Web of Science ®Google Scholar
• Brink M, Meeuwes FO, van der Poel MWM, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140(9):1009–1019. doi:10.1182/blood.2021015114
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 131(16):1970–1976. doi:10.1200/JCO.2012.44.7524
   PubMed Web of Science ®Google Scholar
• Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018; 131(4):397–407. doi:10.1182/blood-2017-09-806737
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 15123(20):3095–3100. doi:10.1182/blood-2013-12-542142
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Özcan M, Jacobsen ED, et al. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019; 37(8):613–623. doi:10.1200/JCO.18.00899
   PubMed Web of Science ®Google Scholar
• Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014; 25(11):2211–2217. doi:10.1093/annonc/mdu443
   PubMed Web of Science ®Google Scholar
• Cederleuf H, Bjerregård Pedersen M, Jerkeman M, et al. The addition of etoposide to CHOP is associated with improved outcome in ALK + adult anaplastic large cell lymphoma: a Nordic lymphoma group study. Br J Haematol. 2017; 178(5):739–746. doi:10.1111/bjh.14740
   PubMed Web of Science ®Google Scholar
• Deng S, Lin S, Shen J, et al. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. Onco Targets Ther. 2019;12:2335–2342. doi:10.2147/OTT.S189825
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german High-Grade Non-Hodgkin lymphoma study group. Blood. 2010;116(18):3418–3425. doi:10.1182/blood-2010-02-270785
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004; 104(3):634–641. doi:10.1182/blood-2003-06-2095
   PubMed Web of Science ®Google Scholar
• Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018; 29(3):715–723. doi:10.1093/annonc/mdx787
   PubMed Web of Science ®Google Scholar
• Savage KJ, Horwitz SM, Advani R, et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022; 6(19):5550–5555. doi:10.1182/bloodadvances.2020003971
   PubMed Web of Science ®Google Scholar
• d‘Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012; 30(25):3093–3099. doi:10.1200/JCO.2011.40.2719
   PubMed Web of Science ®Google Scholar
• Smith SM, Burns LJ, van Besien K, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013; 31(25):3100–3109. doi:10.1200/JCO.2012.46.0188
   PubMed Web of Science ®Google Scholar
• Enewold L, Parsons H, Zhao L, et al. Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020; 2020(55):3–13.
   PubMedGoogle Scholar
• SEER-Medicare. National Cancer Institute. SEER-Medicare: Brief Description of the SEER-Medicare Database. https://healthcaredelivery.cancer.gov/seermedicare/overview/. Accessed 3/15/2023. Available from: https://healthcaredelivery.cancer.gov/seermedicare/overview/.
   Google Scholar
• SEER-Medicare. National Cancer Institute. SEER‐medicare: Calculation of comorbidity weights. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html. Accessed 3/15/2023. Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html.
   Google Scholar
• Morgan CJ. Landmark analysis: a primer. J Nucl Cardiol. 2019;26(2):391–393. doi:10.1007/s12350-019-01624-z
   PubMed Web of Science ®Google Scholar
• Lévesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010; 340(mar12 1):b5087–b5087. doi:10.1136/bmj.b5087
   PubMedGoogle Scholar
• Gordon MJ, Duan Z, Zhao H, et al. A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale. Blood Adv. 2023;Jun 13;7(11):2632–2642.
   Web of Science ®Google Scholar
• Herrera AF, Crosby-Thompson A, Friedberg JW, et al. Comparison of referring and final pathology for patients with T-cell lymphoma in the national comprehensive cancer network. Cancer. 2014; 120(13):1993–1999. doi:10.1002/cncr.28676
   PubMed Web of Science ®Google Scholar
• Sibon D, Fournier M, Brière J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the groupe d‘Etude des lymphomes de l‘Adulte trials. J Clin Oncol. 2012; 30(32):3939–3946. doi:10.1200/JCO.2012.42.2345
   PubMed Web of Science ®Google Scholar
• Yang YT, Tai CJ, Chen C, et al. Highly diverse efficacy of salvage treatment regimens for relapsed or refractory peripheral T-cell lymphoma: a systematic review. PLoS One. 2016;11(10):e0161811. doi:10.1371/journal.pone.0161811
   PubMed Web of Science ®Google Scholar
• Chihara D, Fanale MA, Miranda RN, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017; 176(5):750–758. doi:10.1111/bjh.14477
   PubMed Web of Science ®Google Scholar
• Stuver RN, Khan N, Schwartz M, et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019; 94(6):641–649. doi:10.1002/ajh.25463
   PubMed Web of Science ®Google Scholar
• Ma H, Cheng B, Falchi L, et al. Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. Hematol Oncol. 2020; 38(1):51–58. doi:10.1002/hon.2705
   PubMed Web of Science ®Google Scholar
• Shipp M. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993; 329(14):987–994.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;1103(7):2474–2479. doi:10.1182/blood-2003-09-3080
   PubMed Web of Science ®Google Scholar